Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

141.08 +0.03 (+0.02%)
Delayed Quote Updated: 9:30 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
News headline image
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? ↗
Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains. 
Via The Motley Fool
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile ↗
Via Chartmill
News headline image
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride. 
Via The Motley Fool
News headline image
Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022 ↗
The pharmaceutical giant's track record in past bear markets is fairly impressive. 
Via The Motley Fool
Topics Economy Intellectual Property Stocks
Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors ↗
Via Chartmill
News headline image
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares ↗
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease. 
Via Investor's Business Daily
News headline image
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns. 
Via The Motley Fool
Topics ETFs
News headline image
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much. 
Via The Motley Fool
News headline image
Amgen Drops 10% on a Trial It Didn't Even Run ↗
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact. 
Via MarketBeat
News headline image
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks ↗
Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks. 
Via Benzinga
News headline image
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons ↗
Crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, today, Sept. 8, 2026. 
Via The Motley Fool
Topics Artificial Intelligence Stocks World Trade
News headline image
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower ↗
Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials. 
Via Benzinga
News headline image
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling ↗
Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations. 
Via Benzinga
News headline image
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma ↗
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday. 
Via Investor's Business Daily
News headline image
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session ↗
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined. 
Via Benzinga
News headline image
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners ↗
Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares. 
Via Benzinga
News headline image
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday ↗
Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected. 
Via Benzinga
News headline image
Novartis, Ionis Tumble On Surprise Flop For Heart Drug ↗
Novartis' Ionis-partnered Lp(a) blocker failed in testing. Both stocks fell. 
Via Investor's Business Daily
News headline image
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths ↗
Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns. 
Via Benzinga
Topics Death
News headline image
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win ↗
Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals. 
Via Benzinga
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Why Novartis Just Surged 6%, Eyeing A Breakout ↗
Novartis stock surged early Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies. 
Via Investor's Business Daily
News headline image
VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? ↗
Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks. 
Via MarketBeat
Topics ETFs
News headline image
Breakfast News: A Conversation With Ionis CEO ↗
Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more. 
Via The Motley Fool
Topics ETFs World Trade
News headline image
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? ↗
PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names. 
Via The Motley Fool
Topics ETFs
News headline image
PPH vs. IYH: Which Healthcare Fund Is the Better Buy? ↗
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings. 
Via The Motley Fool
Topics ETFs
News headline image
This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem ↗
The JPMorgan International Value ETF (JIVE) has outpaced the S&P 500 this year, offering low-volatility, diversified international exposure with a 1.22% yield and rising institutional demand. 
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
News headline image
The L.A. Lakers Delivered a 1-Year Return of 25%. These ETFs Have Done Even Better. ↗
Most people don't have $12.5 billion to buy the L.A. Lakers. But with stock ETFs, you could earn a higher return than the Lakers' owners. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help. ↗
Want to put your money into global stocks that might be big winners from AI? These two low-cost ETFs offer international diversification. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better. 
Via The Motley Fool
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.